IDEAYA Biosciences

Tango Therapeutics

This biotechnology company develops precision oncology medicines targeting genetic vulnerabilities in cancer cells for patients with solid tumours.

Fore Biotherapeutics

This precision oncology company develops targeted therapies for patients with unaddressed cancer mutations, including a specific BRAF inhibitor for advanced solid tumours.

Black Diamond Therapeutics

This clinical-stage company develops precision oncology medicines and small molecule therapies for patients with genetically defined cancers.

D3 Bio

This biotechnology company develops precision medicines and oncology therapeutics for patients with cancer and immunological conditions.

Fore Bio

This biotechnology company develops precision oncology therapies and small-molecule inhibitors for patients with unaddressed tumour mutations and hard-to-treat cancers.

Acrivon Therapeutics

This biopharmaceutical company develops precision oncology medicines and proteomics-based companion diagnostics for cancer patients.

Aprea Therapeutics

This company develops targeted cancer therapies for patients with biomarker-defined tumours and DNA damage response pathway defects.

iOnctura

The company develops precision small-molecule medicines to treat patients with neglected and hard-to-treat solid tumours and cancers.